多药新辅助化疗改善早期胰腺癌生存:美国国家癌症数据库分析
基于美国国家癌症数据库2010-2014年I/II期可切除胰腺腺癌患者,比较不同化疗时序与类型的总生存。多药新辅助化疗较直接手术及其他化疗方案均改善中位OS,新辅助联合辅助化疗优于单独新辅助或辅助化疗。
要点
- I/II期可切除胰腺癌中,新辅助化疗较直接手术中位OS延长5个月。
- 多药新辅助化疗优于单药辅助、单药新辅助和多药辅助化疗。
- 新辅助联合辅助化疗生存优于单独新辅助或单独辅助化疗。
核心结论
- 在I/II期可切除胰腺腺癌患者中,多药新辅助化疗较直接手术及其他化疗时序(除新辅助联合辅助化疗外)均改善中位总生存。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列分析,纳入2010-2014年诊断的临床I/II期可切除胰腺腺癌患者18,470例,采用最小距离匹配策略构建五组1:1比较。
主要发现
- 新辅助化疗对比直接手术:每组3271例,中位OS 28.1 vs 23.2个月,P<0.0001,HR 0.79。
- 多药新辅助化疗对比单药辅助、单药新辅助和多药辅助化疗:每组1349例,中位OS 30 vs 25.9个月,P=0.0001,HR 0.82。
- 多药新辅助化疗对比多药辅助化疗:每组1349例,中位OS 30 vs 26.1个月,P=0.0008,HR 0.86。
- 新辅助联合辅助化疗对比单独新辅助化疗:每组1128例,中位OS 31.6 vs 27.4个月,P=0.0011,HR 0.81。
- 新辅助联合辅助化疗对比单独辅助化疗:每组1128例,中位OS 31.6 vs 25.2个月,P<0.0001,HR 0.76。
临床怎么用
- I/II期可切除胰腺腺癌患者可考虑多药新辅助化疗,并可能从术后辅助化疗中进一步获益。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare overall survival (OS) in patients who underwent surgery for early-stage pancreatic adenocarcinoma (rPca) based on sequence (NAT, neoadjuvant therapy and/or AT, adjuvant therapy) and type (SA, single-agent or MA, multi-agent) of chemotherapy received. METHODS: Using the National Cancer Database, patients with clinical stage I/II rPca diagnosed between 2010 and 2014 were identified and five comparison matches (1: NAT vs. upfront resection (UR); 2: multi-agent neoadjuvant (MA NAT) vs. single-agent adjuvant therapy (SA AT), single-agent neoadjuvant therapy (SA NAT), multi-agent adjuvant therapy (MA AT); 3: MA NAT vs. MA AT; 4: NAT + AT vs NAT; 5: NAT + AT vs AT) were constructed using minimum distance matching strategy. Median OS (mOS) was analysed using Kaplan-Meier method, log-rank test and Cox proportional hazard model. RESULTS: A total of 18,470 patients with stage I/II rPca were eligible for analysis. NAT showed a 5 month (mo.) improved OS compared with UR (3271 patients/group, 28.1 vs 23.2 mo. P < 0.0001 hazard ratio [HR]: 0.79). MA-NAT was shown to be superior to other chemotherapy approaches SA AT, SA NAT, and MA AT (1349 patients/group: 30 vs. 25.9 mo., P = 0.0001 [HR: 0.82]). MA NAT showed a survival advantage over MA-AT (1349 patients/group, 30 vs 26.1 mo., P = 0.0008 [HR: 0.86]). The combination of NAT and AT showed a better outcome when compared with NAT alone (1128 patients/group, 31.6 vs 27.4 mo., P = 0.0011 [HR: 0.81]) or AT alone (1128 patients/group, 31.6 vs. 25.2 mo., P < 0.0001 [HR: 0.76]). CONCLUSIONS: In patients with stage I/II rPca, MA NAT showed improved mOS compared to UR and all other chemotherapy sequences except both NAT plus AT. These findings support the use of MA NAT in stage I/II rPca patients and warrant prospective trials evaluating MA NAT and post-resection maintenance therapies.
引用
- Deng A, Wang C, Cohen SJ, et al. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis. Eur J Cancer. 2021. PMID: 33607382. doi:10.1016/j.ejca.2021.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。